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Review
Federal agencies such as the Food and Drug 
Administration (FDA), National Toxicology 
Program (NTP), National Institute of 
Occupational Safety and Health (NIOSH), 
and National Institute of Environmental 
Health Sciences (NIEHS) devote substan-
tial resources to evaluating chemical hazards. 
However, chemical product manufacturers 
have conducted the great bulk of toxicological 
testing and research used in regulatory safety 
assessments. For substances whose regulation 
requires pre  approval (e.g., pharmaceuticals, 
food additives, and pesticides), regulatory 
frameworks require companies to conduct spe-
cific tests [Federal Food, Drug, and Cosmetic 
Act (FFDCA) 1938; Federal Insecticide, 
Fungicide, and Rodenticide (FIFRA) of 
1972]. The U.S. Environmental Protection 
Agency (EPA) also has the power, by rule, 
order, or negotiated outcome, to direct com-
panies to test chemicals they manu  facture or 
process (or propose to manufacture or pro-
cess) [Toxic Substances Control Act (TSCA) 
1976]. In addition, companies routinely eval-
uate potential hazards and risks of their prod-
ucts to assure a safe workplace, for product 
stewardship, and to limit potential liability. 
As a result, industry-conducted or -funded 
research provides the bulk of the science rele-
vant to assessing chemical safety, and this is 
not likely to change (Barden et al. 2006).
For almost as long as industry has been 
conducting research involving chemicals, 
skeptics have challenged the credi  bility 
of that work. They have described inten-
tional genera  tion of false or mis  leading data 
(Hirschhorn 2000) and research that seems 
directed to increasing doubt about health 
effects (Michaels 2008). Critics have argued 
that industry-supported work has employed 
methods, animal strains, or other test features 
that tend to miss or under  estimate adverse 
effects (Myers et al. 2009). Commonly, no 
more specific criticism is leveled than that 
the results of the work tend to support the 
use, rather than restriction, of the chemical 
(Kissinger and Rust 2008). News and social 
media increasingly imply that industry sup-
port of scientific work is alone sufficient to 
invalidate it (Popken 2008). Even though 
the source of funding has been asserted to 
be a “less significant” cause of publication 
bias than other causes (e.g., academic pressure 
to publish) (DeMaria 2004; Fanelli 2010), 
industry support suffices for many to vitiate 
the credibility of scientific work.
The volume of industry-supported stud-
ies of chemicals is burgeoning now with the 
European Union’s implementation of its 
Registration, Evaluation, Authorisation and 
Restriction of Chemical substances (REACH) 
system (Hartung and Rovida 2009), and an 
amended TSCA in the United States could 
drive additional chemical testing, even if 
REACH data are considered for TSCA pur-
poses (Safe Chemicals Act of 2011). But how 
will massive increases in the quantity of such 
data improve public confidence in the U.S. 
chemical regulatory system if industry-sup-
ported work is perceived as inherently dubi-
ous? Absent significant action to address that 
perception, we seem inexorably headed toward 
an outcome in which landmark legislation and 
substantial investments in research and testing 
produce little or no improvement in public 
confidence in either the safety of chemical 
products or the effectiveness of the system 
designed to assure it.
A Necessary Solution: 
Consensus Criteria for 
Assessing Scientific Credibility
The crux of any solution to this problem of 
legitimacy in chemical evaluation is a means for 
assessing the trust  worthiness of a study regard-
less of its funding source. A widely accepted 
set of objective criteria for assessing credibility, 
applicable by any interested person, is needed.
As we document here, there is already 
wide agreement on such criteria. Three sets 
of criteria proposed in 2009 by independent 
groups of experts, as well as two similar sets 
published recently, demonstrate a remark-
able degree of convergence among them. This 
convergence augurs well for the prospect of a 
formalized system of credibility assessment, 
which could arise from a consensus process, 
a regulatory initiative, or both. To facilitate 
such an effort, we conclude our review by 
discussing issues that any such systemization 
effort would necessarily have to address.
Credibility Distinguished 
from Reliability
Conventionally, the ultimate measure of a sci-
entific work’s validity is how broadly and con-
fidently its conclusions become accepted in 
the relevant field, which in turn derives from 
the extent to which its findings are replicated 
and extended. However, establishing such 
validity, especially for a novel experimental 
finding, can take years, and what constitutes 
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replication or extension may be disputed for 
some time.
As a result, the policy-making community 
has evolved a variety of short-term proxies 
for evaluating the merits of a scientific work. 
The best known of these is Klimisch et al.’s 
criteria-based system for evaluating a study’s 
“reliability” for use in hazard or risk assess-
ment (Klimisch et al. 1996). This system “is 
the most widely used system” of its sort (Dor 
et al. 2009), and the European Commission 
has supported development of a software-
based tool (the “ToxRTool”) to extend and 
operationalize it (Schneider et al. 2009).
However, reliability alone is not a suf-
ficient condition. Equally necessary is a proxy 
that addresses the credibility of a given work, 
that is, the likelihood that it faithfully reflects 
what was observed, is not the product of 
unconscious bias or intentional manipulation, 
and is thus believable. Such a proxy should 
be applicable to all sources of funding, and 
across all affiliations of investigators, because 
questions can also arise about the credibility 
of research by scientists funded by govern-
ment agencies or non  profit organizations. 
Without broad agreement on objective means 
for determining the credibility of research and 
testing, public confidence in regulatory evalu-
ations and product stewardship programs will 
not improve. To facilitate progress, we pro-
pose Klimisch-like criteria for assessing the 
credibility of studies in light of any funding 
source or affiliation.
Sources and Methodology
The genesis of this article was a session at 
the annual meeting of the Society for Risk 
Analysis (SRA) in December 2009 at which 
speakers presented three strikingly similar sets 
of criteria for evaluating scientific credibility: 
• David Goldston presented a Bipartisan Policy 
Center (BPC) report titled “Improving the 
Use of Science in Regulatory Policy” (BPC 
2009). This report represents the work of 
13 distinguished academic, business, and 
non  profit representatives, many of whom 
have held senior scientific or policy posi-
tions within government. It includes consen-
sus recommendations on four topics, one of 
which is a discussion of “basic principles” for 
how federal agencies should filter and evalu-
ate “studies rele  vant to regulatory policy” 
(BPC 2009).
• Eric Hentges and Sanford Miller presented 
a report of a panel of 14 other academic 
and industry experts organized under the 
aegis of the International Life Sciences 
Institute (ILSI). The report, published in the 
American Journal of Clinical Nutrition (Rowe 
et al. 2009), presents “guiding principles” for 
“health, nutrition and food safety science.” 
• One of the authors of this review (J.W.C.) 
presented a slightly updated version of an 
earlier article (Henry and Conrad 2008) that 
identified “standards and practices currently 
being used [that] assist in judging the quality 
of research and testing . . . regardless of why 
the work was conducted” (Conrad 2009). 
Each of the criteria presented either 
a) increases confidence that the sponsor 
or experimenter did not shape or skew the 
results or interpretation of an experiment; 
or b) enables others to assess independently 
whether such shaping or skewing occurred.
Further confirming our convergence the-
sis, two similar sets of credibility criteria have 
been published by the International Agency for 
Research on Cancer (IARC) and the Federation 
of American Societies for Experimental Biology 
(FASEB). The IARC (2008) document is ori-
ented toward a broader purpose (a code of 
good scientific practice), and the FASEB docu-
ment (Brockway and Furcht 2006) toward bio-
medical research, but many of their elements 
are comparable to the criteria discussed at the 
SRA meeting and thus are also discussed here.
Here, we attempt to advance the fore  going 
literature by demonstrating the degree of com-
monality among the five sets of criteria, synthe-
sizing them into a discrete set, and exploring 
issues that would have to be addressed in any 
effort to systematize application of the criteria.
Here, we have intentionally omitted two 
potential criteria. First, we do not propose that 
funding by industry (or any other source that 
could be perceived to have a biasing effect) 
should be itself a criterion of lack of credibility, 
because that would be anti  thetical to science: 
“The observing scientist is only an accessory 
in the acquisition of scientific evidence, where 
the facts are asked to first speak for themselves” 
(Borgert 2007). A question about the source of 
funding merely serves to trigger application of 
the criteria. Second, we do not propose consid-
ering whether a third party adminis  tered the 
funding of scientific work (e.g., Cohen et al. 
2009) because such a mecha  nism seems too 
costly and complicated to be applied broadly 
under REACH or TSCA. There are clearly 
situations where such third-party adminis-
tra  tion of research efforts has been fruitful, 
such as the Health Effects Institute (2010) 
program on the health effects of air pollution. 
Although such an approach perhaps could be 
employed to investigate basic research areas of 
a select set of commodity chemicals, it is diffi-
cult to envision for regulatory scientific studies 
within a modernized TSCA that would need 
to deal with the approximately 15,000 chemi-
cals that the U.S. EPA estimates are currently 
in commerce (U.S. EPA 2010a). However, 
full consideration should be given to use of 
independent third-party entities to evaluate 
and verify regulatory testing systems within 
companies or consortia for scientific integrity, 
to provide input into complex study designs 
or testing protocols of substances of high social 
concern, and to conduct peer review of major 
testing reports, especially studies that are not 
published in scientific journals.
Proposed Credibility Criteria
The 10 proposed criteria are shown in 
Table 1, along with information on the extent 
to which a given criterion is contained in 
the five publications (or the presentation) on 
which this article is based. In the table, the 
check mark (✓) indicates complete or sub-
stantial adoption, the qualified check mark 
(~✓) indicates partial adoption, and the dash 
(—) indicates absence. The criteria are ranked 
by how broadly they are contained within the 
five under  lying publications and are ranked 
in rough order of importance within those 
groups. 
Below we explain these criteria more fully, 
highlighting considerations that warrant fur-
ther discussion regarding how each criterion 
might be applied. We frankly acknowledge, 
as did Klimisch et al. (1996), that judgment is 
inherent in that process. This is not fatal to the 
overall concept, but rather another reason why 
a consensus or governmental process should be 
undertaken to promote discussion of the crite-
ria and how they could be systematized. 
Criterion 1: Whether the principal investi-
gator (PI) has fully disclosed sources of funding 
and other “competing interests.” To control 
for the prospect that a study’s funding source 
might lead to bias, the most essential element 
is disclosure of funding sources. There may be 
legitimate circumstances in which such dis-
closure is not possible; for example, a historic 
study may not disclose funding sources. Still, 
as stated by the BPC (2009), “agencies and 
scientific advisory committees should be wary 
of studies when it is unclear who funded the 
study or whether the principal investigator(s) 
had any conflicts of interest.” 
Notably, this criterion is not limited to 
funding from “industry”; it anticipates that 
PIs will disclose all sources of financial sup-
port received, whether by grant or by con-
tract, in support of the relevant work. This 
is the perspective of the BPC (2009), IARC 
(2008), and Henry and Conrad (2008).
Biasing financial interests may also arise 
from sources beyond those funding the 
research. Concerns about the biasing effect of 
investigators’ financial interests have, for exam-
ple, led the U.S. Department of Health and 
Human Services (DHHS) and the National 
Science Foundation (NSF) to issue investiga-
tor conflict of interest policies (DHHS 1995; 
NSF 2005); both require grant applicants to 
disclose “significant financial interests” of the 
PIs or their immediate family that “would rea-
sonably appear to be affected” by the research 
proposed to be funded. Most journals simi-
larly require prospective authors to disclose 
all “competing interests” [e.g., Environmental Enhancing credibility of chemical safety studies
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Health Perspectives (EHP) 2010]. Consistently, 
the five under  lying articles go beyond disclo-
sure of funding sources to call for “full signed 
disclosure of all financial interests” (Rowe et al. 
2009), disclosure of “any conflicts of interest” 
(BPC 2009), or “acknowledge[ment of] all 
forms of external support” (IARC 2008), or at 
least note the growth of “competing financial 
interests policies” (Henry and Conrad 2008). 
The FASEB guidelines (Brockway and Furcht 
2006) are particularly explicit about the range 
of relationships that should be disclosed by 
investigators, including funding, consulting, 
equity ownership, and any other “significant 
financial interests.”
As the BPC (2009) noted, substantial 
thought should be devoted to determining 
what constitutes a conflicting or competing 
interest and to balancing the goal of promot-
ing disclosure against investigators’ legitimate 
interests in privacy and minimizing burdens. 
The BPC and Henry and Conrad (2008) both 
recommended the National Academies (2003) 
policy on this topic as a good model. The BPC 
(2009) also noted the disagreement within 
its own panel regarding whether disclosure 
should be limited to current interests. (The 
DHHS and NSF policies apply only to current 
interests, whereas EHP’s policy and the BPC 
require 3- and 2-year look-backs, respectively.) 
There is thus much work to be done on this 
criterion by any future consensus or govern-
mental effort to formalize this approach. But 
there is wide agreement on the core elements 
and their importance.
Criterion 2: Whether the PI is legally 
guaranteed the right to a) publish the results 
of the study without prior sponsor approval, 
b) analyze and interpret the resulting data, 
and, where appropriate, c) control the study 
design. Right to publish. All five of the under-
lying sets of credibility criteria also agree that 
reliable science involves the PI, by written 
agreement with the funding source, having 
the right to publish the study results without 
prior sponsor approval. This substantially bol-
sters the work’s credibility because it gives the 
PI authorial control and prevents the spon-
sor from being able to conceal or selectively 
release results.
This criterion does not prevent the PI from 
agreeing to share a draft study protocol, prog-
ress report, or draft article or report with the 
sponsor, because a) the PI and the study spon-
sor may wish to consult about whether observed 
effects are reportable under applicable law; 
b) pre  publication review could be necessary for 
the sponsor to secure intellectual property rights 
in the study subject (Brockway and Furcht 
2006); and c) sponsor comment could result 
in a more accurate report (Henry and Conrad 
2008). If prepublication review is anticipated, 
this criterion requires prior delineation of the 
permissible basis for review and applicable time 
limits. Such provisions would help to guard 
against unjustified deferral of publication that 
could be caused by extensive or repeated rounds 
of comments or by undue delay in the sponsor 
providing comments to the PI.
The ILSI report and IARC code went 
beyond guaranteeing the PI’s right to pub-
lish by requiring a written agreement that 
“obligat[es the PI] to attempt to publish the 
findings within some specified timeframe” 
(Rowe et al. 2009) or speaking of a “duty to 
publish” (IARC 2008). Further discussion 
of this criterion should specifically consider 
whether a publication obligation is appro-
priate for all types of scientific work (e.g., 
product testing) or where publication is not 
a goal of the PI. A system to implement this 
criterion might award extra “credit” where 
publication occurs.
Control of data analysis/interpretation. 
Henry and Conrad (2008) endorsed the prac-
tice of the American Chemistry Council’s 
Long-Range Research Initiative to give its 
PIs owner  ship of resulting data (American 
Chemistry Council 2009). They explained 
that doing so “lend[s] strength, objectivity, 
Table 1. Criteria for assessing the credibility of scientific work.
Proposed criterion BPCa  ILSIb  Henry and Conradc 
IARC Code of Good 
Scientific Practiced
FASEB Guidelines  
on “Conflict of Interest  
in Biomedical Research”e
1. Disclosure of funding sources 
and other competing interests
✓ ✓ Scope limited to industry 
funding; other sources 
warrant thought
✓ ✓ ✓ Scope limited to industry 
funding
2. PI is legally guaranteed  
a) Freedom to publish  ✓  ✓ Must attempt to publish 
within some time frame 
✓ ✓ Duty to publish  ✓ 
b) Authority to analyze and 
interpret results 
— ~ ✓ PI must have control of 
statistical analysis 
✓ PI must own data  — ~ ✓ PI must be involved in 
analysis and interpretation 
of results 
c) Control of study design ✓  ✓  — —  — 
3. Public release of data and 
methods
✓ ~ ✓ PI and “appropriate 
auditors/reviewers” must 
have access to all data
✓ For data; does not address 
methods
~ ✓ Requests for 
use of data “to 
be encouraged”
~ ✓ PI should make 
reasonable efforts to 
provide data and materials 
to other investigators
4. Factual and transparent 
research objective and 
appropriate research design
— ✓ ✓ Recognizes value of GLP 
[value of Common Rule 
noted (Conrad 2009)] 
✓ ✓
5. Peer review ✓ ✓ “Mandatory prerequisite” 
for effectiveness of 
guidelines
✓ ✓ Duty to publish 
in peer-reviewed 
journal
—
6. Prior listing in a public 
registry (where exists)
✓ — — — —
7. No linkage of remuneration 
to outcome of experiment
— ✓ — — —
8. Disclosure of paid “name 
lending”
— ✓ — — —
9. Maintain clarity between 
CRO and academic auspices
— ✓ — — —
10. External review of research 
program
— — ✓ (Conrad 2009)  — —
Abbreviations: CRO, contract research organization; GLP, Good Laboratory Practice; PI, principal investigator. The check mark (✓) indicates complete or substantial adoption; the 
qualified check mark (~ ✓) indicates partial adoption; and the dash (—) indicates absence.
aBPC (2009). bRowe et al. (2009). cHenry and Conrad (2008). dIARC (2008). eBrockway and Furcht (2006).Conrad and Becker
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and credibility to the outcome of the research” 
because “when investigators own the data and 
the scientific information that they gener-
ate . . . they are in control of how those data 
will be evaluated, used and communicated” 
(Henry and Conrad 2008). No other set of cri-
teria discussed here specifies that investigators 
must own data, presumably because sponsors 
often need to retain owner  ship of data for reg-
ulatory purposes or to preserve patent or other 
legal protections. On the other hand, a PI does 
not have to own data to be given independent 
control in analyzing it. The result is the same: 
the sponsor has no legal basis to prevent the PI 
from independently interpreting the data.
The ILSI report stated that investigators 
must be “guarantee[d] control of statistical 
analysis” of data (Rowe et al. 2009), and the 
FASEB guidelines stated that investigators 
“shall have access to, and be involved in, the 
analysis and/or interpretation of all data gener-
ated in the research” (Brockway and Furcht 
2006). Going slightly beyond these formula-
tions, the criterion we propose requires that the 
PI explicitly be given independent authority to 
analyze and interpret the study results.
Control of research design. The BPC 
(2009) and the ILSI (Rowe et al. 2009) speci-
fied that the PI should also retain control of the 
study design. Neither discussed the issue in any 
detail, which is unfortunate because there may 
well be circumstances where this requirement 
is not fully appropriate. Certainly, PI control of 
study design would seem to be of questionable 
applicability in cases where the design of the 
study is determined in advance by explicit regu-
latory agency direction. For example, FIFRA 
and TSCA require adherence to test guide-
lines that prescribe experimental study design 
elements (U.S. EPA 1989a, 1989b), and the 
Organization for Economic Cooperation and 
Development (OECD 1998) imposes simi-
lar requirements. Finally, the Animal Welfare 
Act (1966) required study designs involving 
animal models to be reviewed and approved 
in advance by an institutional animal care and 
use committee (IACUC). IACUC approval 
requires considera  tion of numerous study 
design elements, including justification of the 
animal model, number of animals, procedures 
for animal care, and approaches to monitor 
and address pain and distress.
The credibility of the study is certainly 
boosted where control of study design is 
given to the PI, and so the proposed criterion 
requires it where feasible. (The appropriate-
ness of the chosen design is an important but 
separate issue, covered under criterion 4.)
Criterion 3: Whether the investigator or 
sponsor has publicly released the research data 
or test method to allow others to review them 
and seek to replicate the analysis. Although it 
is important for PIs to have the legal right to 
release study results, it is equally important 
from a credibility perspective for the PI or 
the sponsor to release the under  lying data and 
methods, so that others can evaluate how well 
the study supports the claimed conclusion 
(or some other alternative, plausible conclu-
sion). The ability to interpret data or replicate 
results typically also requires knowledge of the 
research or test method employed. Hence, this 
criterion rewards prompt dissemination of data 
and methods by publication in the scientific 
literature, submission of the results to the gov-
ernment, or other similar public distribution.
This criterion is likely to be controversial 
because academic scientists have not tradi-
tionally released the actual data underlying 
their studies, at least initially. Scientific jour-
nal publications generally include only a sum-
marization of experimental procedures and 
summary tables or figures; laboratory study 
records and raw data are typically retained 
by the PI. Nor do most academic investi-
gators adhere to GLP requirements, which 
require government access to complete study 
records and data sets (FDA 2006; U.S. EPA 
2010b). Often, academics intend to publish 
several articles from a data set and do not 
want to reduce the prospect or impact of later 
publications by releasing the data. Mindful 
of these sensitivities, the IARC (2008) code 
stated a principle of “full and contemporane-
ous documentation of research methods [and] 
data,” but it provided that the “principle[] in 
practice” requires only that “requests for use 
of the data should be encouraged, with due 
regard to the terms on which the data were 
obtained and stipulations that may have been 
made.” The FASEB guidelines (Brockway and 
Furcht 2006) adopted a similar approach: 
“Once a study is published, academic investi-
gators should make reasonable efforts to pro-
vide data and materials to other investigators 
for replication purposes.”
In contrast, the “Shelby Amendment” 
(Omnibus Appropriations Act 1998) and 
Circular A-110 of the Office of Management 
and Budget (OMB 1999) require federal 
agencies to make publicly available, via the 
Freedom of Information Act (FOIA 1966), 
final research data generated by agency grant-
ees that an agency cites in support of a rule or 
order. It seems only fair for privately funded 
work to be subject to the same disclosure 
requirement, at least when the persons con-
ducting or funding it submit it to an agency. 
This is the position taken by the BPC (2009). 
[Henry and Conrad (2008) contended that 
agencies actually have that disclosure obliga-
tion whenever they rely on privately funded 
information, as a result of the Information 
Quality Act (IQA 2000) and the OMB IQA 
guidelines (OMB 2002).] Particular research 
may involve confidential business information 
[e.g., proprietary data or software that cannot 
be publicly disclosed without violating the 
intellectual property rights of the vendors or 
inventor (who may be the PI)]. FOIA protects 
such information, although due process or 
administrative law concerns may be triggered 
if an agency relies on non  public data.
Outside of the contexts where federal law 
requires disclosure of data, some form of com-
promise or accommodation on the topic may 
be appropriate. The ILSI report (Rowe et al. 
2009) called for “guarantee[ing] accessibil-
ity to all data and control of statistical analy-
sis by investigators and appropriate auditors/ 
reviewers.” A more demanding standard might 
be to expect release of under  lying data and 
methods by some reasonable period of time 
after initial publication. Alternatively, there 
may be ways the PI can describe the data or 
methods sufficiently to enable evalua  tion with-
out revealing specific intellectual property.
Disclosing all results of a study, not just 
those that can be summarized in a journal 
article, permits regulatory agencies to inde-
pendently evaluate the integrity of study 
data, verify the authors’ conclusions, and, if 
needed, analyze the results using alternative 
procedures. The space restrictions imposed 
by paper journals limit their ability to publish 
data and thus impede the use by agencies of 
studies reported solely in such journals. The 
Internet circumvents this limitation, however, 
and so the practice of scientific journals such 
as EHP of enabling investigators to post sup-
plemental data online is bound to increase. 
Although such supplemental information is 
not fully equivalent to the complete data sup-
plied for a GLP study, it likely will not be 
long before such data posting becomes the 
norm. Therefore, the scientific and regula-
tory communities need to accelerate develop-
ment of standardized toxicological data sets 
that capture the information required to ade-
quately describe a study for deposition into 
online databases (Fostel et al. 2007).
Criterion 4: Whether the investigator con-
ducted research that was designed objectively 
and reported factually, so that, according to 
accepted principles of scientific inquiry, the 
research design adequately tests an appro-
priately phrased hypothesis. This criterion, 
adapted from the ILSI report (Rowe et al. 
2009), is self-evident. The credibility of stud-
ies assessing the safety of chemical products 
depends critically on the ability to have con-
fidence in their procedures and the result-
ing data (Becker et al. 2009), and the most 
important procedural aspect may be that the 
research design not favor a particular out-
come. This has become a hotly contested 
issue. For example, some argue that tradi-
tional toxicity testing methods that follow 
U.S. EPA or OECD test guidelines and GLP 
methods are “out of date” and “insensitive” 
and thus “incapable of detecting low-dose 
endocrine-disrupting effects” (Myers et al. Enhancing credibility of chemical safety studies
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2009). On the other side, criticisms related 
to study design have been leveled at academic 
studies for using irrelevant exposure routes 
(NTP–Center for the Evaluation of Risks to 
Human Reproduction 2007).
Importance of agency test guidelines 
and GLPs. Henry and Conrad (2008) previ-
ously presented a detailed discussion of the 
GLP regulations that the U.S. EPA and FDA 
require experimenters to follow in conducting 
studies to be submitted under FIFRA, TSCA, 
and FFDCA (FDA 2006; U.S. EPA 1989a, 
1989b). Henry and Conrad (2008) discussed 
how these rules require experimenters to 
a) document study conduct and results; b) cre-
ate and use written standard operating proce-
dures (SOPs); and c) follow agency-approved, 
validated study protocols. Maintenance of 
complete study records and data sets allows 
independent verification of critical study ele-
ments such as a) develop  ment and adherence 
to SOPs and protocols for each study com-
ponent; b) dosing techniques; c) use of group 
sizes adequate to provide meaningful statistical 
analysis; d) analytical characteri  zation of test 
and control substances with respect to iden-
tity, purity, and concentration; e) the verac-
ity of recording of study measure  ments and 
data; and f) incorporation of quality control 
procedures and independent quality assurance 
reviews. For these reasons, the Klimisch et al. 
(1996) criteria award “the highest grade of 
reliability” to studies that follow “internation-
ally accepted test guidelines . . . and the prin-
ciples of . . . GLP,” as do systems following 
them (Dor et al. 2009; Küster et al. 2009). 
The same features that render guideline-
compliant GLP studies reliable also make 
them more credible because they enable one 
to say confidently that the PI followed the 
specified protocol, actually took the steps and 
measure  ments claimed to have been taken, 
and accurately reported the results. Four of 
the five under  lying sets of criteria note this 
fact expressly (Henry and Conrad 2008), 
constitute a code of good scientific practice 
(IARC 2008), or call for PIs to adhere to such 
standards (Brockway and Furcht 2006; Rowe 
et al. 2009). Accordingly, we recommend that 
any implementation of this criterion judge 
studies meeting GLPs as more credible than 
those that do not.
This recommendation may draw criticism 
from scientists who do not follow standardized 
test guidelines and GLPs and would object 
to the additional costs and effort inherent in 
doing so. However, when such studies are sub-
mitted to or considered by agencies for policy 
purposes, it seems only appropriate to regard 
them as less credible than studies that follow 
test guidelines and GLPs, where applicable.
As Klimisch et al. (1996) recognized, there 
is an inherent dynamic tension between stan-
dardized and validated test methods and new, 
cutting-edge scientific methodologies that aca-
demic researchers develop and apply to evaluate 
new hypotheses. Both have important roles and 
provide valuable data. Options for establishing 
the requisite degree of confidence in new meth-
ods or novel findings include traditional struc-
tures for conducting method validation (e.g., 
the Interagency Coordinating Committee on 
the Validation of Alternative Methodologies) 
or using approaches such as evidence-based 
toxicology (Guzelian et al. 2005; Hoffmann 
and Hartung 2006) or those discussed by the 
National Research Council (2007). 
Good epidemiology practices. For epi-
demiology studies, the guidelines for 
Good Epidemiological Practice (GEP) 
(International Epidemiological Association 
2007) and the similar “Guidelines for Good 
Pharmacoepidemiology Practices” (GPP) 
provide “minimum practices and procedures 
that should be considered to help ensure 
the quality and integrity . . . and to provide 
adequate documentation of research methods   
and results” (International Society for 
Pharmacoepidemiology 2007). However, the 
extent to which epidemiologi  cal studies pub-
lished in scientific journals meet such profes-
sional society best practices is unclear because 
authors do not typically include this informa-
tion in publications.
GEP/GPPs require many of the same 
credibility-related features as GLPs: a detailed 
research protocol based on a stated hypothe-
sis before the study starts; data collection, 
analysis, and storage procedures; and quality 
control measures. [GEP/GPPs also provide 
reliability-related guidance on reaching causal 
inferences derived from the Hill criteria (Hill 
1965).] Although none of the under  lying 
sets of criteria discuss GEP/GPPs, we believe 
that PIs of epidemiological studies should be 
encouraged to meet them and to so indicate 
in their articles. Future discussion of this cri-
terion should consider judging epidemiology 
studies meeting GEP/GPPs as more credible 
than those that do not. This would also pres-
ent an opportunity to discuss whether the 
model of an independent work group, similar 
to a pathology working group, could provide 
greater credibility for particularly influential 
epidemiological studies.
Involvement of outside experts in study 
design and choice of method. Another factor 
that justifies greater credibility in a study’s 
design or a new method is whether it was 
chosen (or that choice was reviewed) by out-
side experts. Thus, according to the IARC 
(2008) code, “The study design and choice 
of method . . . should have passed through a 
scientific review.” This factor will usually be 
satisfied in cases where government regula-
tions or conditions specify the study design, 
because those requirements generally have 
been developed with external scientific review. 
Where external expert involve  ment is feasible, 
a study should be regarded as more credible 
when it occurred.
Conformance to the “Common Rule” 
is an additional index of credibility. The 
Common Rule protects the rights and wel-
fare of human research subjects and governs 
human subjects research conducted, funded, 
or regulated by federal agencies (DHHS 
1991). [Human subjects research not directly 
covered by the Common Rule must nonethe-
less conform to it in order to be considered 
by the U.S. EPA in connection with its pesti-
cide program (U.S. EPA 2006).] Comparable 
guidelines also exist for research conducted 
outside the United States (e.g., World Medical 
Association 1964). A key element of the 
Common Rule is the use of an institutional 
review board (IRB) to review the proposed 
research for ethicality. Among the criteria that 
the IRB must apply is that any risks to the sub-
jects be “reasonable in relation to anticipated 
benefits, if any, to subjects, and the impor-
tance of the knowledge that may reasonably 
be expected to result from the work” (DHHS 
1991). In order to produce new knowledge, 
research has to be designed and conducted in 
ways that will produce reliable results; in par-
ticular, it must contain a signifi  cant and clearly 
articulated study question, and its design must 
be sufficiently rigorous to answer that ques-
tion. Therefore, a human study’s conformance 
to the Common Rule or an international 
equivalent is another independent basis for 
concluding that this criterion is satisfied, and 
such a study should be judged more credible 
than a non  conforming study.
Criterion 5: Whether the work was peer 
reviewed. Virtually all of the underlying pub-
lications recognized the centrality of peer 
review. Henry and Conrad (2008) observed 
that a “rigorous peer review is a key part of the 
foundation on which scientific excellence is 
achieved in all research programs.” The BPC 
(2009) stated that “papers in high impact, peer 
reviewed journals should be given great weight, 
and papers that have not been peer-reviewed 
should be treated with skepticism.” The ILSI 
report (Rowe et al. 2009) did not specify peer 
review as one of its guiding principles but 
declared that a “strong peer review system . . . is 
a mandatory pre  requisite for these guidelines 
to be effective.” Likewise, the IARC (2008) 
code spoke of the “duty to publish . . . in peer-
reviewed scientific publications.”
BPC (2009) also recognized that “the 
quality of peer review varies widely” and that 
agencies “need to extend their inquiry beyond 
simply ascertaining whether a paper was peer 
reviewed,” potentially to include “how the 
peer review was conducted.” (BPC also pro-
posed ways to strengthen the peer review pro-
cess.) Henry and Conrad (2008) emphasized 
the major differences between journal peer Conrad and Becker
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review and the “more demanding” reviews 
that OMB’s Peer Review Bulletin (OMB 
2005) imposes on federal agencies regarding 
science they propose to rely on—particularly 
“highly influential scientific assessments.” 
The U.S. EPA’s Science Advisory Board, 
the NTP’s Board of Scientific Counselors, 
and similar government-administered panels 
exhibit a level of thoroug  ness and transpar-
ency not charac  teristic of journal peer review 
when they peer review individual studies. (The 
Peer Review Bulletin does not require a panel 
considering a risk assessment or similar review 
of an integrated set of studies to review the 
under  lying studies individually.) Accordingly, 
this criterion regards studies that have under-
gone governmental peer review pursuant to 
the Peer Review Bulletin as more credible than 
those that have not.
We decline to adopt the BPC’s (2009) 
proposed higher weight for “high impact” 
journals, given the uncertainty about where 
the line should be drawn between “high” 
and “low” impact and the prospect that this 
approach might import a degree of publica-
tion bias into the reliability assessment process.
Finally, additional discussion of this cri-
terion should address the important role of 
histo  pathological evaluations in determining 
adverse effects in toxicological studies. For 
“pivotal general toxicology studies” the Society 
of Toxicologic Pathology (STP) recommended 
that a second pathologist independently review 
the slides to arrive at more solid decisions (STP 
1991), and in some cases a formal pathology 
working group can be convened (Ward et al. 
1995). The STP position papers on reporting 
pathological findings (Morton et al. 2006) 
and pathology peer review (Morton et al. 
2010) provided up-to-date discussions of these 
important elements of GLP toxicology studies.   
Clearly, an independent pathology review, 
conducted in accordance with STP guidelines, 
increases the credibility of a toxicity study.
Criterion 6: Whether, before its com-
mencement, the study was included on a public 
registry of research intended for use in policy 
making. The BPC (2009) report highlighted 
the growth of public study registries, the best 
known of which is ClinicalTrials.gov, which 
Congress required the National Institutes of 
Health (NIH) to establish for clinical trials of 
certain pharmaceuticals (NIH 2010). Where 
such a registry exists, the BPC report recom-
mended that agencies consider registered stud-
ies and “be wary of studies that met the criteria 
for the registry, but were not registered.”
One benefit of clinical trial registries is that 
sponsors are required to alert the world that 
they are initiating a study and cannot await the 
outcome before deciding whether to announce 
it. Another is that neither the sponsors nor 
the PI can redefine the purpose of a study to 
match what was found rather than what was 
initially hypothesized. A third is that such regis-
tries may promote the publication of negative 
results, a needed corrective to the increasingly 
recognized problem of publication bias and its 
tendency to produce over  statements of toxic-
ity, efficacy, or other variables being assessed 
(DeMaria 2004; Sena 2010).
Although there do not yet appear to be 
formal registries for toxicological and epi-
demiological studies of the sort involved in 
chemical safety testing, there is no reason why 
an agency such as the U.S. EPA, or various 
private entities, could not establish one. The 
U.S. EPA has experience in implementing a 
publicly accessible database containing test 
plans and results from the High Production 
Volume Challenge program (U.S. EPA 
2010b), and the NTP has long maintained 
a database that includes chemicals the orga-
nization is currently testing and substances 
that have completed testing (NTP 2010). 
Similarly, the Risk Information Exchange 
is an Internet database containing notifica-
tions about a variety of human health risk 
assessment projects in progress or recently 
completed (Alliance for Risk Assessment 
2010). Thus, it appears reasonably feasible to 
establish such a registry for toxicological and 
epidemiological studies, open to all studies 
regardless of sponsor. The proposed criterion 
would regard a study as more credible if, once 
such a registry is established, the study had 
been timely registered.
Criterion 7: Whether the PI’s remunera-
tion was geared to a particular experimental 
outcome. Compensation contingent upon 
results would seem the very essence of a con-
flict between the interests of truth and the 
experi  menter and the antithesis of credibility. 
Accordingly, ILSI listed as a guiding principle 
that investigators not accept such remunera-
tion when conducting experimental studies 
(Rowe et al. 2009). Going further, we believe 
that an agreement to pay a PI on such a con-
tingent basis renders a study inherently not 
credible and warrants its outright exclusion 
from agency consideration.
Criterion 8: Whether a sponsor or a PI 
participated in an arrangement by which 
the sponsor would pay the PI to lend his or 
her name to a presentation or article actually 
drafted by someone else. Attention is increas-
ingly being devoted to the phenomenon of 
parties seeking to leverage the reputations of 
esteemed scientists to boost the credibility 
of their product or activity. The ILSI prin-
ciples included a prohibition on such reputa-
tion trading (Rowe et al. 2009). The DHHS 
has proposed to treat “paid authorship” as a 
“significant financial interest” (DHHS 2010) 
requiring disclosure and potential manage-
ment under its investigator conflict of interest 
policy discussed above. Under this criterion, 
an article or presentation would be regarded as 
less credible if the nominal author had not in 
fact contributed substantially as an author or 
investigator but had accepted compensation to 
allow the actual author to use his or her name.
Criterion 9: Whether a PI working under 
the auspices of a contract research organization 
(CRO) or other entity has maintained clarity 
between that entity and the PI’s academic or 
other affiliations. In the ILSI report, Rowe 
et al. (2009) noted that academic researchers 
who are also affiliated with other non  academic 
institutions will sometimes contract to con-
duct research at the latter organization (i.e., 
the CRO) but, when publishing the results of 
that research, will list their academic affiliation 
(Rowe et al. 2009). As with the author  ship 
phenomenon discussed above, this practice 
improperly trades on reputa  tion. As with the 
prior criterion, if this practice occurs, the study 
should be regarded as less credible.
Criterion 10: Whether the sponsoring 
organization employs systematic external   
review of research and testing programs 
to promote a culture of scientific integrity. 
Organizational dynamics do not sponta-
neously promote frank internal review. As 
a result, passive controls to ensure scientific 
integrity are now viewed as insufficient, and 
institutions are moving to pro  active activities 
to educate and reinforce honesty, accuracy, 
and objectivity in research (DHHS 2006). At 
times, even internal procedures can become 
dated and less than optimally effective. The 
practice adopted by several major U.S. chemi-
cal products companies to counter such ten-
dencies includes periodically asking highly 
respected independent experts to conduct sys-
tematic reviews of their research and testing 
programs (Conrad 2009). 
Any organization—public or private—that 
sponsors research could benefit from such a 
process, and this criterion judges a study spon-
sored by an organization employing the process 
as more credible. Future delibera  tion should 
address how the process could be objectively 
and readily verified.
The Next Step: A Formalized 
System of Credibility 
Assessment
There is already an encouraging convergence, 
across a wide range of experts and organizations, 
on the criteria that should be used to assess the 
credibility of scientific work. Establishing a 
simi  lar consensus on a system to reproducibly 
apply the criteria will require much work, how-
ever, to resolve the following issues.
Foreseeable controversies. Several of the 
criteria conflict with legitimate and strongly 
held values among relevant communities. 
Academic researchers in particular are likely to 
be concerned about criterion 3 (public release 
of data and methods), especially insofar as 
it provides greatest credit for full and timely Enhancing credibility of chemical safety studies
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 6 | June 2011  763
release, and criterion 4 (research design) to 
the extent that it provides greatest credit for 
GLP-compliant studies. Protection of con-
fidential business information will also be 
important to the private sector in connection 
with criterion 3.
Missing criteria? Because this article is 
a review, we are limited to the criteria con-
tained in the five publications under review 
(although we do propose expanding some of 
them). An important next step would be to 
determine whether any other criteria warrant 
inclusion. For example, fair questions can be 
asked about whether sponsors are engaging the 
most knowledgeable investigators. Discourse 
on this issue should begin with the recognition 
that different purposes of scientific investiga-
tion (i.e., basic or applied research) can lead to 
different selection processes.
Academic basic research, research in its 
purest sense, is focused on increasing funda-
mental scientific knowledge. Basic research 
develops and evaluates new hypotheses, cre-
ates novel methods, and uses these to probe 
the limits of current understanding. Basic 
research is typically funded by research grants, 
which foster the scientific process by allowing 
considerable latitude in the research program.
In contrast, applied research tends to focus 
on defined aspects of a question and to employ 
well-established methods. Applied research 
is typically funded by contracts rather than 
grants, and these contracts charac  teristically 
specify in considerable detail the scope of the 
effort and the types of procedures to be used. 
This is especially true for toxicology studies 
required to comply with agency test guide-
lines. Although requests for proposals can be, 
and often are, used for applied research, it is 
also common practice for the private sector to 
employ focused solicitation of specific CROs 
or specific individual PIs. Sponsors may elect 
to contract with a specific CRO or PI that they 
feel has qualifications, expertise, and a track 
record of meeting regulatory requirements for 
study design, conduct, and reporting. Such an 
approach can lead to concern that industry may 
be selecting scientists whose previous work has 
concurred with an industry position. However, 
concerns about the process of selecting investi-
gators can be assuaged by the credibility criteria 
discussed above. Thus, applied research should 
not be viewed as less credible when it is con-
ducted through a focused solicitation.
Qualitative or quantitative? The next 
issue to be explored in considering how to 
establish a system of credibility assessment is 
whether the criteria should simply be used as 
a list of factors to be considered, or whether 
studies should be “scored” numerically against 
them. The former, qualitative approach has 
considerable precedent, including the Hill 
(1965) considerations. Nonetheless, such an 
approach leaves enormous discretion to users 
and is unlikely to be reproducible by differ-
ent individuals or panels. Also, some criteria 
seem intuitively more important than oth-
ers (indeed, in this article we rank them in 
part on that basis) and a numerical approach 
would enable consistent weighting of criteria. 
We thus favor exploration of a system that 
would score studies against the criteria, with 
specific numbers of points or credits available 
under each criterion. Such an approach must 
yet grapple with several issues, each of which 
will require thoughtful debate.
•	Relative	weighting.	It is one thing to agree 
that some criteria are more important than 
others but quite another to agree on how 
much weight each deserves.
•	Binary	or	continuum? A criterion might sim-
ply be satisfied or not—criterion 6 (inclu-
sion on a registry) is a good example. Others, 
however, might be applicable in a graded 
way that could result in assignment of more 
points as the criterion was more fully satisfied. 
This approach would seem most applicable to 
criteria 4 (research design and conduct) and 5 
(peer review).
•	Should	any	criteria	be	grounds	for	disquali-
fication? A study that fails to meet a criterion 
might simply receive no credit. Alternatively, 
the criterion might be deemed so fundamen-
tal that failure to satisfy it renders a study 
inherently not credible, as we have proposed 
for criterion 7 (compensation geared to 
experimental outcome).
•	Normalization.	Many aspects of the crite-
ria will not always be applicable to a specific 
study; for example, a PI has little freedom to 
design an agency-required test guideline/GLP 
study, and no widely established registry of 
toxicity studies yet exists. Other aspects may 
be the basis for purely “bonus” points on 
the theory that they are always potentially 
applicable (e.g., whether a study was subject 
to governmental peer review). The design of a 
scoring system would require careful thought 
about how to take account of these aspects.
•	Who	can	use	the	system? Because govern-
ment agencies are charged with determining 
the safety of chemicals, the proposed criteria 
are principally intended for those agencies. 
There is no question, however, that broad 
use by a range of stakeholders is inevitable—
the strongest argument for developing a 
credibility scoring system that is readily use-
ful and reproducible.
Next steps. For a credibility assessment sys-
tem itself to have credibility, the fore  going 
issues need to be addressed by a group of 
stakeholders with diverse perspectives. This 
could occur through some sort of formal 
consensus process, a governmental initiative, 
or both. In either case, it will be crucial to 
reach out to potentially affected parties and 
to actively seek practical input on specific 
  questions and   examples.
It particular, it would be wise to conduct 
a pilot of any proposed credibility assess-
ment system. The pilot could a) identify a 
range of studies that are relevant to a given 
safety assessment, including industry-funded 
guideline/GLP studies, agency-conducted 
laboratory studies, agency contractor studies, 
academic studies, and studies sponsored by 
non  governmental organizations; b) conceal 
the identity of the chemical in question to 
minimize potential bias; c) have a number of 
experts score each study using the criteria; and 
then d) compile and compare the results to 
assess the degree of concordance among the 
assigned scores.
Unprecedented efforts will be devoted to 
toxicity testing and research in the coming 
years to meet growing public and regulatory 
demand for chemical safety information. It 
would be profoundly wasteful if all stake-
holders do not act now to ensure that, when 
this information is developed, an effective 
system exists for assuring the public that the 
research is credible.
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